Common side effects and medication precautions of baricitinib

Baricitinib, also known as baricitinib, is an oral JAK inhibitor that mainly acts on JAK1 and JAK2 signaling pathways, commonly used in the treatment of moderately to severely active rheumatoid arthritis (RA), as well as in the treatment of new coronavirus pneumonia in some cases. As an immunomodulatory drug, baricitinib effectively relieves joint inflammation, pain and disease progression by inhibiting key inflammatory signaling. However, behind its good efficacy, there is also a certain risk of side effects, and patients need to pay special attention when taking it.

1. Common side effects

1.Increased risk of infection

Baricitinib inhibits the JAK pathway in the immune system. Although it plays an important role in alleviating autoimmune inflammation, it also weakens the body's ability to resist infection. This makes patients more likely to develop mild to moderate infections such as respiratory tract infections, urinary tract infections, and oral ulcers during medication, and may even induce herpes zoster, tuberculosis, or serious bacterial infections in individual cases. Therefore, before taking baricitinib, patients should undergo a tuberculin test or interferon release test to rule out potential risks of infection.

2.Abnormalities in the blood system

Some patients taking baricitinib experience a decrease in thrombocytopenia, red blood cells, or white blood cell count during treatment. Especially in the early stages of medication, it is recommended to regularly monitor blood routine in order to detect abnormalities in time and adjust the dose or suspend medication if necessary.

3.Liver function and dyslipidemia

Baricitinib may cause increases in liver function markers (e.g., ALT, AST), as well as increases in cholesterol and triglyceride levels. Therefore, it is recommended to regularly test liver function and blood lipids before and during treatment. Especially patients with existing lipid metabolism disorders or liver disease should be used under the supervision of a doctor.

4. Thrombotic events

Some studies and drug instructions have pointed out that the use of baricitinib may increase the risk of deep vein thrombosis or pulmonary embolism, and should be used with caution in patients with a history of thrombosis, obesity, and long-term bed rest. If the patient develops leg swelling, difficulty breathing, chest pain and other symptoms during medication, he should seek medical attention immediately.

2. Medication precautions

1.Taboos and people who should use with caution

In principle, baricitinib is not recommended for people with active infections (such as tuberculosis, sepsis, etc.), people with severe liver and kidney dysfunction, pregnant women, lactating women, and adolescents under the age of 18. Use of this drug by pregnant women may have adverse effects on the fetus, so a strict pregnancy evaluation should be conducted before use and effective contraceptive measures should be taken during treatment.

2.Check before taking medication

Before starting treatment with baricitinib, a comprehensive health assessment should be conducted, including blood routine, liver and kidney function, blood lipid levels, hepatitis B/ hepatitis C virus screening, tuberculosis testing, etc., to evaluate whether the patient is suitable for taking the drug and to develop a personalized medication plan.

3.Interactions with other drugs

Baricitinib has potential interactions with certain drugs. For example, concomitant use with strong OAT3 inhibitors (such as probenecid) may increase baricitinib plasma concentrations and require dose adjustment or avoidance of concomitant use. At the same time, when used in combination with other immunosuppressants (such as biological agents, cyclophosphamide, etc.), the risk of infection caused by superimposed immunosuppression should be weighed.

4.Monitoring and adjustment during treatment

During the medication process, patients need to receive regular follow-up monitoring to evaluate the therapeutic effect and side effects of the medication. If serious adverse reactions occur, the doctor may recommend suspending or discontinuing the medication. For those whose symptoms improve slowly or are ineffective, it may be necessary to change the treatment plan.

3. Suggestions on rational medication use

Although baricitinib has certain side effects, as long as it is used rationally under the guidance of a doctor, its effect in relieving inflammation and improving quality of life is still certain. To minimize risk, patients should do the following:

Take medication strictly as directed by your doctor, and do not adjust the dosage or stop medication on your own;

Avoid blind combination with other immunosuppressants;

If you experience any symptoms of discomfort, please report it to your doctor promptly for prompt treatment;

Maintain a healthy lifestyle, such as regular work and rest, avoiding smoking and drinking, and eating a balanced diet to improve the body's immunity.

4. Summary

Baricitinib, as aJAK inhibitor, provides an effective new treatment path for rheumatoid arthritis and other autoimmune diseases. By targeting inflammatory signaling pathways, it alleviates disease progression from the root cause and helps patients regain their quality of life. However, because its mechanism of action is closely related to the immune system, some patients may experience side effects such as infection, blood abnormalities, and abnormal liver function during use. Therefore, risk monitoring should be paid attention to during medication, and follow-up visits and physical examinations should be reasonably arranged to ensure a balance between efficacy and safety. The ultimate goal is to help patients obtain the best treatment results with controllable risks.

Reference materials:https://www.drugs.com/